{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T04:46:28Z","timestamp":1697345188439},"reference-count":7,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2011,1,11]],"date-time":"2011-01-11T00:00:00Z","timestamp":1294704000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the American Academy of Nurse Practitioners"],"published-print":{"date-parts":[[2011,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p> <jats:bold>Purpose:<\/jats:bold> This article reviews current trends for using pharmacotherapy in combination with other weight loss modalities and offers points for consideration by clinicians in practice.<\/jats:p><jats:p> <jats:bold>Data sources<\/jats:bold>: Selected evidence\u2010based articles and government websites.<\/jats:p><jats:p> <jats:bold>Conclusions<\/jats:bold>: Pharmacotherapy as a strategy for managing overweight, obese, and extremely obese individuals remains controversial. Risk versus benefit and overall safety of prescription drugs for weight loss management remains a primary focus for consideration among clinicians and a viable topic for evidence\u2010based outcomes research.<\/jats:p><jats:p> <jats:bold>Implications for practice<\/jats:bold>: Overweight and obesity are well accepted as critical risk factors and predictors of morbidity and mortality in individuals of all ages from childhood to senescence. In the United States, overweight and obesity exist in epidemic proportions. It is critical that primary care providers be knowledgeable about pharmacologic factors related to obesity.<\/jats:p>","DOI":"10.1111\/j.1745-7599.2010.00587.x","type":"journal-article","created":{"date-parts":[[2011,1,11]],"date-time":"2011-01-11T10:42:23Z","timestamp":1294742543000},"page":"61-66","source":"Crossref","is-referenced-by-count":1,"title":["Overweight and obesity: Pharmacotherapeutic considerations"],"prefix":"10.1111","volume":"23","author":[{"given":"Nancy","family":"Balkon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig","family":"Balkon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce S.","family":"Zitkus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,1,11]]},"reference":[{"key":"e_1_2_7_2_1","unstructured":"Clinicaltrials.gov.2010.A long term study of sibutramine and the role of obesity management in relation to cardiovascular disease in overweight and obese patients (SCOUT). Last updated May 6 2010. Study completed November 2009."},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003114"},{"key":"e_1_2_7_4_1","first-page":"3","volume-title":"Pharmacology: Drug therapy and nursing considerations","author":"Malseed R. T.","year":"1994"},{"key":"e_1_2_7_5_1","unstructured":"Sherry B. Blanck H. M. Galuska D. A. Pan L. Dietz H. W. &Balluz L.(2010).Vital signs: State\u2010Specific obesity prevalence among adults \u2014 United States 2009.Morbidity and Mortality Weekly Reviews August 3 2010 Retrieved October 2010 fromhttp:\/\/www.cdc.gov\/mmwr\/pdf\/wk\/mm59e0803.pdf"},{"key":"e_1_2_7_6_1","unstructured":"U.S. Food and Drug Administration. (2010a).Postmarket drug safety information\u2013\u2013 Fen\u2010Phen. Retrieved October 2010 fromhttp:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm179871.htm"},{"key":"e_1_2_7_7_1","unstructured":"U.S. Food and Drug Administration. (2010b).Postmarket drug safety information \u2013 Meridia. Retrieved October 2010 fromhttp:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm191652.htm"},{"key":"e_1_2_7_8_1","unstructured":"U.S. Food and Drug Administration. (2010c).Safety information \u2013 Orlistat. Retrieved October 2010 fromhttp:\/\/www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/SafetyAlertsforHumanMedicalProducts\/ucm213448.htm"}],"container-title":["Journal of the American Academy of Nurse Practitioners"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1745-7599.2010.00587.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1745-7599.2010.00587.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T20:28:11Z","timestamp":1697315291000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1745-7599.2010.00587.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,11]]},"references-count":7,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["10.1111\/j.1745-7599.2010.00587.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1745-7599.2010.00587.x","archive":["Portico"],"relation":{},"ISSN":["1041-2972","1745-7599"],"issn-type":[{"value":"1041-2972","type":"print"},{"value":"1745-7599","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,11]]}}}